Real-time enrollment status for this relapsed refractory multiple myeloma clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 2:35 PM UTC
| NCT Number | NCT07391657 |
| Recruiting Status | Recruiting |
| Condition | Relapsed Refractory Multiple Myeloma |
| Phase | PHASE3 |
| Target Enrollment | 508 participants |
| Active Locations | 51 sites in the US |
| Sponsor | AstraZeneca |
| Last Updated on CT.gov | September 29, 2026 (1 week ago) |
As of October 12, 2026: Clinical trial NCT07391657 is currently recruiting participants. This phase3 study for relapsed refractory multiple myeloma is actively seeking new participants at 51 locations across the United States. The study is sponsored by AstraZeneca. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07391657 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 51 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07391657 was last updated 1 week ago (September 29, 2026). HelloStudys verifies this status automatically.